Investigating the Role of Salvage Lymph Node Dissection in Nonmetastatic CRPC
Traditionally, approaches to the management of patients with nonmetastatic CRPC following radical prostatectomy have been limited.
Androgen-deprivation Therapy
Early ADT for Recurrent Prostate Cancer Challenged
Men with biochemically recurrent nonmetastatic prostate cancer following radical prostatectomy have long survival times from the time of surgery without hormonal treatment, a study found.
ASCO Releases Guideline on Addressing Osteoporosis Risk With Nonmetastatic Cancer
The guideline includes strategies to identify patients with nonmetastatic cancer who may be at a higher risk for osteoporotic fractures.
Prostate Cancer ADT Raises Dementia Risk, Study Finds
Androgen deprivation therapy for prostate cancer is associated with a significant 20% increased risk of dementia and 14% increased risk of Alzheimer’s disease, a study found.
Non-Standard Therapies Used in 20% of Localized High-Risk PCa Cases
Using EBRT alone or ADT alone for high-risk localized prostate cancer is associated with worse survival outcomes.
Lower Testosterone Threshold May Benefit ADT Recipients
New study shows prolonged time to development of castration-resistant prostate cancer among men with absolute testosterone levels below 20 ng/dL.
Low Carb Diet + Walking May Ease ADT’s Adverse Effects
In a small study, men on androgen deprivation therapy for prostate cancer lost weight and experienced improved hemoglobin A1C and lipid profiles.
Prostate Cancer ADT May Reduce Autoimmune Disease Risk
Androgen deprivation therapy recipients had a significantly lower risk for autoimmune diseases overall and for Graves’ disease, uveitis, and psoriasis.
New Surrogate Marker for ADT Evaluation Proposed
Time interval free of biochemical failure may be a potential surrogate end point in the setting of androgen-deprivation therapy evaluation in men with prostate cancer.
ADT May Be Less Beneficial for Gleason 9 to 10 Prostate Cancer
Men with Gleason score 9 to 10 prostate cancer derive no significant survival benefit from androgen deprivation therapy.
Next post in Prostate Cancer
